Medtronic plc (ETR: 2M6)
Germany
· Delayed Price · Currency is EUR | Market Cap | 109.75B |
| Revenue (ttm) | 30.49B |
| Net Income (ttm) | 3.96B |
| Shares Out | n/a |
| EPS (ttm) | 3.02 |
| PE Ratio | 27.70 |
| Forward PE | n/a |
| Dividend | 2.59 (3.03%) |
| Ex-Dividend Date | Dec 27, 2024 |
| Volume | 336 |
| Average Volume | 1,237 |
| Open | 84.48 |
| Previous Close | 83.49 |
| Day's Range | 84.29 - 85.48 |
| 52-Week Range | 70.10 - 86.00 |
| Beta | 0.85 |
| RSI | 74.45 |
| Earnings Date | Feb 18, 2025 |
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accesso... [Read more]
Financial Performance
In 2024, Medtronic's revenue was $32.36 billion, an increase of 3.64% compared to the previous year's $31.23 billion. Earnings were $3.68 billion, a decrease of -2.18%.
Financial numbers in USD Financial StatementsNews
Medtronic plc (MDT) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Medtronic CEO Geoff Martha sits down with Jim Cramer
Medtronic CEO Geoff Martha joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk its Parkinson's treatment, partnering with SpaceX, products in the pipeline, and more.
CMS to conduct analysis for Medtronic's Symplicity Spyral
Medtronic announces CMS national coverage analysis for Symplicity™ Spyral Renal Denervation System
National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure Milestone is supported by large public health need and robust, long-term ...
Medtronic achieves CE Mark approval for BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's through innovative brain-computer interface technology
European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease GALWAY, Ireland , Jan. 13, 2025 /PRNewswire/ -...
J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product
Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system.
Is Medtronic's Dividend Safe?
Medtronic: Scoop Up This Dividend Aristocrat On Sale Now
Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division
Medtronic will act as the exclusive sales agent of MagnetOsTM for Kuros Biosciences USA, Inc. in mutually agreed upon sales territories for use in spine surgeries Kuros will work collaboratively to se...
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division
Kuros Biosciences AG / Key word(s): Agreement Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division 07-Jan-2025 / 07:00 CET/CEST Release of an ad ho...
Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference
GALWAY, Ireland , Jan. 6, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 43rd annual J.P. Morgan healthcare confere...
Medtronic: A Dividend Aristocrat That's Poised To Pop
2 Cheap Dividend Aristocrats to Buy for 2025
#Morningstar #DividendArtisocrats #StockInvesting These reliable dividend stocks look significantly undervalued today. 00:00 Introduction 00:39 Federal Realty Trust FRT 01:25 Medtronic MDT Susan Dziu...
My Best Dividend Aristocrats For January 2025
The ProShares S&P 500 Dividend Aristocrat ETF rocked a cool 4.85% gain in November, but it's giving up nearly half of its return this year in December. I present 3 strategies that can theoretically be...
Medtronic Stock Is Still A Great "Buy"
Financial writer predicts Medtronic's stock will rise due to recent product launches and improved margins, reaffirming a Buy rating for 2025.
Looking Into Medtronic's Recent Short Interest
Medtronic's (NYSE: MDT) short percent of float has fallen 16.13% since its last report. The company recently reported that it has 10.01 million shares sold short , which is 0.78% of all regular share...
Jim Cramer takes a closer look at the medtech space
'Mad Money' host Jim Cramer takes a closer look at Medtronic, Edwards, and Idexx.
Medtronic continues losses for seven straight sessions
Medtronic (MDT) shares continue to decline, but analysts are still bullish on the stock despite concerns about the company's bottom line.
Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends
"Dividend Aristocrats
Medtronic PLC (MDT) Announces Third Quarter Cash Dividend for Fiscal Year 2025
Medtronic PLC (MDT) Announces Third Quarter Cash Dividend for Fiscal Year 2025
Medtronic announces cash dividend for third quarter of fiscal year 2025
GALWAY, Ireland , Dec. 5, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal y...
Acutus Medical announces workforce reduction by 70%
Acutus Medical (AFIB) to reduce workforce by 70% and focus on supporting Medtronic products.
Price Over Earnings Overview: Medtronic
Looking into the current session, Medtronic Inc. (NYSE: MDT) shares are trading at $85.62, after a 1.06% decrease. Over the past month, the stock fell by 4.53% , but over the past year, it actually i...
Medtronic: Guidance Raised, Solid Dividend, Shares Still A Bargain
Best Long-Term Investment Stocks to Buy
Some of the best long-term investment stocks include companies that are in good financial standing, have a low valuation and pay consistent dividends.